查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1635987

2025-2033 年腎癌治療和診斷市場報告（按成分、癌症類型、應用和地區）

Kidney Cancer Therapeutics and Diagnostics Market Report by Component, Cancer Types, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

2024 年，全球腎癌治療和診斷市場IMARC Group達到 54 億美元。腎癌發病率上升、老年人口增加以及多個政府的有利舉措是推動市場發展的一些關鍵因素。

腎癌是一種慢性疾病，腎臟組織出現異常細胞生長，進而轉變為腫瘤。其症狀包括尿血、食慾不振、腰痛、疲倦、發燒、體重減輕、骨痛、高血壓和貧血。腎癌可透過多種技術診斷，例如血液和尿液檢查、活體組織切片、生物標記測試、電腦斷層掃描(CT) 掃描、X 光、磁振造影(MRI)、膀胱鏡檢查和腎單位輸尿管鏡檢查。它可以透過藥物、化療、放射治療、腎切除術、冷凍消融、射頻消融和標靶治療來治療。腎癌治療和診斷有助於清除癌細胞、破壞腫瘤並防止復發，並協助醫生規劃治療方案。它們還有助於改善腎功能、減少未來併發症、控制癌症擴散並提高患者舒適度。

腎癌治療與診斷市場趨勢：

由於吸煙習慣、肥胖、遺傳條件和化學物質接觸的日益普遍，腎癌發病率不斷上升，這是推動市場成長的主要因素之一。腎癌治療和診斷廣泛用於分析和治療腎細胞癌(RCC)、良性腎腫瘤、腎母細胞瘤、移行細胞癌、腎肉瘤、髓樣癌、多房性囊性腎細胞癌以及黏液性管狀細胞癌和梭形細胞癌。此外，對腎細胞癌和其他形式腎癌高度易感性的老年人口不斷增加，促進了對治療和診斷方法的需求，以控制腫瘤、延長生存期和保護腎臟的非癌症部分。此外，最近開發的能夠檢測生物標記的診斷工具，例如桿狀病毒 IAP 重複序列 5 (BIRC5)，是早期檢測透明細胞腎細胞癌和預測患者預後的關鍵指標，正在對市場成長產生積極影響。除此之外，引入3D (3D) 列印來創建腎臟及其腫瘤的術前模型，從而幫助醫生製定治療計劃並為患者提供適當的諮詢，減少手術錯誤，增強效率和保留大部分腎功能有利於市場成長。此外，政府實施的各種旨在傳播癌症意識的措施正在為市場創造積極的前景。預計其他因素包括醫療保健行業的顯著成長、為確定潛在治療方案而對研發 (R&D) 活動的投資不斷增加，以及機器人手術、遠距醫療和人工智慧 (AI) 等先進技術的廣泛採用以進一步推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球腎癌治療和診斷市場的表現如何，未來幾年將如何表現？
  • 全球腎癌治療和診斷市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的腎癌治療和診斷市場？
  • 基於組件的市場區隔是什麼？
  • 根據癌症類型分類的市場是怎麼樣的？
  • 基於應用程式的市場區隔是什麼？
  • 全球腎癌治療與診斷市場的競爭結構如何？
  • 誰是全球腎癌治療和診斷市場的主要參與者/公司？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球腎癌治療與診斷市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：按組成部分

  • 藥品
    • 市場趨勢
    • 關鍵環節
      • 藥品：依治療類別
        • 標靶治療
        • 免疫療法
        • 其他
      • 藥品：依藥理分類
        • 血管新生抑制劑
        • mTOR抑制劑
        • 單株抗體
        • 細胞激素免疫治療（II-2）
    • 市場預測
  • 診斷
    • 市場趨勢
    • 關鍵環節
      • 影像學檢查
      • 活體組織切片
      • 驗血
      • 其他
    • 市場預測

第 7 章：市場區隔：按癌症類型

  • 透明細胞腎細胞癌
    • 市場趨勢
    • 市場預測
  • 乳頭狀腎細胞癌
    • 市場趨勢
    • 市場預測
  • 嫌色腎細胞癌
    • 市場趨勢
    • 市場預測
  • 移行細胞癌
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按應用

  • 醫院
    • 市場趨勢
    • 市場預測
  • 製藥實驗室
    • 市場趨勢
    • 市場預測
  • 基因組實驗室
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Bristol-Myers Squibb Company
    • Exelixis Inc.
    • Genentech Inc. (Roche Holding AG)
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112025A7528

The global kidney cancer therapeutics and diagnostics market size reached USD 5.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5.9% during 2025-2033. The rising incidences of kidney cancer, increasing geriatric population, and favorable initiatives by several governments represent some of the key factors driving the market.

Kidney cancer is a chronic disease where abnormal cell growth occurs in kidney tissues, which turns into tumors. Its symptoms include blood in urine, loss of appetite, flank pain, tiredness, fever, weight loss, bone pain, high blood pressure, and anemia. Kidney cancer is diagnosed through various techniques, such as blood and urine tests, biopsy, biomarker testing, computed tomography (CT) scan, X-ray, magnetic resonance imaging (MRI), cystoscopy, and nephron-ureteroscopy. It can be treated through medications, chemotherapy, radiation therapy, nephrectomy, cryoablation, radiofrequency ablation, and targeted therapy. Kidney cancer therapeutics and diagnostics aid in the removal of cancer cells, destroy tumors and prevent recurring, and assist physicians in planning treatments. They also help in improving kidney function, reducing future complications, controlling cancer spread, and enhancing patient comfort.

Kidney Cancer Therapeutics and Diagnostics Market Trends:

The rising incidences of kidney cancer due to the increasing prevalence of smoking habits, obesity, genetic conditions, and exposure to chemicals is one of the primary factors driving the market growth. Kidney cancer therapeutics and diagnostics are widely used to analyze and treat renal cell carcinoma (RCC), benign kidney tumors, Wilms tumors, transitional cell cancer, renal sarcoma, medullary carcinoma, multilocular cystic RCC, and mucinous tubular and spindle cell carcinoma. Furthermore, the rising geriatric population with high susceptibility to renal cell carcinoma and other forms of kidney cancer is facilitating the demand for therapeutics and diagnostics to manage tumors, prolong survival, and preserve noncancerous parts of the kidney. Additionally, the recent development of diagnostic tools capable of detecting biomarkers, such as baculoviral IAP repeat containing 5 (BIRC5), a key indicator for early detection of clear cell RCC and predicting patient prognosis, is positively influencing the market growth. Apart from this, the introduction of three-dimensional (3D) printing to create pre-operative models of the kidney and its tumors, which, in turn, aids physicians in treatment planning and providing appropriate counseling to the patients, reducing surgical errors, enhancing efficiency, and preserving the majority of kidney functions are favoring the market growth. Moreover, the implementation of various government initiatives to spread awareness regarding cancer is creating a positive outlook for the market. Other factors, including significant growth in the healthcare industry, rising investment in research and development (R&D) activities to identify potential treatment options, and widespread adoption of advanced technologies, such as robotic surgery, telemedicine, and artificial intelligence (AI), are anticipated to drive the market growth further.

Key Market Segmentation:

Component Insights:

  • Drugs
  • Drugs by Therapeutic Class
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Drugs by Pharmacologic Class
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Monoclonal Antibodies
  • Cytokine Immunotherapy (II-2)
  • Diagnostics
  • Imaging Test
  • Biopsy
  • Blood Test
  • Others
  • The report has also provided a detailed breakup and analysis of the kidney cancer therapeutics and diagnostics market based on the component. This includes drugs (therapeutic class (targeted therapy, immunotherapy, and others) and pharmacological class (angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2) and diagnostics (imaging test, biopsy, blood test, and others). According to the report, drugs represented the largest segment.

Cancer Types Insights:

  • Clear Cell RCC
  • Papillary RCC
  • Chromophobe RCC
  • Transitional Cell Carcinoma
  • Others

Application Insights:

  • Hospitals
  • Pharmaceutical Labs
  • Genomic Laboratories
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for kidney cancer therapeutics and diagnostics. Some of the factors driving the North America kidney cancer therapeutics and diagnostics market include increasing incidences of kidney cancer, rising research and development (R&D) expenditure, increasing geriatric population, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global kidney cancer therapeutics and diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global kidney cancer therapeutics and diagnostics market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global kidney cancer therapeutics and diagnostics market?
  • What are the key regional markets?
  • Which countries represent the most attractive kidney cancer therapeutics and diagnostics markets?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the cancer types?
  • What is the breakup of the market based on the application?
  • What is the competitive structure of the global kidney cancer therapeutics and diagnostics market?
  • Who are the key players/companies in the global kidney cancer therapeutics and diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Kidney Cancer Therapeutics and Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Component

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Drugs by Therapeutic Class
        • 6.1.2.1.1 Targeted Therapy
        • 6.1.2.1.2 Immunotherapy
        • 6.1.2.1.3 Others
      • 6.1.2.2 Drugs by Pharmacologic Class
        • 6.1.2.2.1 Angiogenesis Inhibitors
        • 6.1.2.2.2 mTOR Inhibitors
        • 6.1.2.2.3 Monoclonal Antibodies
        • 6.1.2.2.4 Cytokine Immunotherapy (II-2)
    • 6.1.3 Market Forecast
  • 6.2 Diagnostics
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Imaging Test
      • 6.2.2.2 Biopsy
      • 6.2.2.3 Blood Test
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Cancer Types

  • 7.1 Clear Cell RCC
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Papillary RCC
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chromophobe RCC
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Transitional Cell Carcinoma
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmaceutical Labs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Genomics Laboratories
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Bristol-Myers Squibb Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Exelixis Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Genentech Inc. (Roche Holding AG)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Pfizer Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Component (in %), 2024
  • Figure 5: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Cancer Types (in %), 2024
  • Figure 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Kidney Cancer Therapeutics and Diagnostics (Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Kidney Cancer Therapeutics and Diagnostics (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Kidney Cancer Therapeutics and Diagnostics (Clear Cell RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Kidney Cancer Therapeutics and Diagnostics (Papillary RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Kidney Cancer Therapeutics and Diagnostics (Chromophobe RCC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Kidney Cancer Therapeutics and Diagnostics (Transitional Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Kidney Cancer Therapeutics and Diagnostics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Kidney Cancer Therapeutics and Diagnostics (Pharmaceutical Labs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Kidney Cancer Therapeutics and Diagnostics (Genomics Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Kidney Cancer Therapeutics and Diagnostics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Drivers, Restraints, and Opportunities
  • Figure 80: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Value Chain Analysis
  • Figure 81: Global: Kidney Cancer Therapeutics and Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Component (in Million USD), 2025-2033
  • Table 3: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Cancer Types (in Million USD), 2025-2033
  • Table 4: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Kidney Cancer Therapeutics and Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Kidney Cancer Therapeutics and Diagnostics Market: Competitive Structure
  • Table 7: Global: Kidney Cancer Therapeutics and Diagnostics Market: Key Players